Inventiva (NASDAQ:IVA) Trading 5.6% Higher – Time to Buy?

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) traded up 5.6% during mid-day trading on Tuesday . The company traded as high as $3.70 and last traded at $3.7050. Approximately 870,594 shares were traded during mid-day trading, an increase of 75% from the average daily volume of 498,498 shares. The stock had previously closed at $3.51.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on IVA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Wall Street Zen cut Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Truist Financial began coverage on Inventiva in a research report on Thursday, March 19th. They set a “buy” rating and a $13.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $16.56.

Inventiva Stock Up 4.4%

The stock’s 50 day simple moving average is $4.84 and its 200 day simple moving average is $5.36.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $0.01 million for the quarter. As a group, sell-side analysts expect that Inventiva S.A. Sponsored ADR will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On Inventiva

A number of large investors have recently added to or reduced their stakes in IVA. Paradigm Biocapital Advisors LP bought a new stake in Inventiva during the fourth quarter worth about $18,600,000. ADAR1 Capital Management LLC bought a new position in shares of Inventiva during the 4th quarter valued at about $12,601,000. Millennium Management LLC increased its position in shares of Inventiva by 2,267.7% during the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after purchasing an additional 2,540,540 shares during the last quarter. UBS Group AG raised its holdings in shares of Inventiva by 28,881.6% during the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after buying an additional 2,634,580 shares in the last quarter. Finally, SymBiosis Capital Partners LLC purchased a new position in shares of Inventiva during the 4th quarter valued at about $12,090,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.